OMedLive

Online Events

Metastatic Colorectal Cancer

Pediatric Neuroblastoma

Myeloproliferative Disorders

Lung Immunotherapy

Lung Cancer - EGFR

Lung Cancer - ALK

Gastric Cancer

Breast Cancer: HER2 Positive

Breast Cancer: ASCO

Speakers

Metastatic Colorectal Cancer

  • Wen Wee Ma, MBBS

    Wen Wee Ma, MBBS

    Wen Wee Ma, MBBS

    Senior Associate Consultant, Medical Oncology

    Wen Wee Ma, MBBS, is a senior associate consultant in the Division of Medical Oncology at Mayo Clinic, Rochester, Minnesota. He is a board-certified medical oncologist with expertise in gastrointestinal oncology and developmental therapeutics. His research focuses on early phase anti-cancer drug development, and the application in gastrointestinal malignancies, including colorectal and pancreatic cancers. Prior to joining Mayo Clinic in 2016, he was an associate professor of oncology and directed the gastrointestinal cancers drug development program at Roswell Park Cancer Institute in Buffalo, New York. He has authored and co-authored over 50 publications, including those in high impact journals such as New England Journal of Medicine and Journal of Clinical Oncology.
  • Joleen M. Hubbard, MD

    Joleen M. Hubbard, MD

    Joleen M. Hubbard, MD

    Assistant Professor of Oncology

    Joleen M. Hubbard, MD, is assistant professor of medical oncology at Mayo Clinic in Rochester, Minnesota, where is also the chair of the Gastrointestinal Tumor Group Practice. She specializes in the treatment of gastrointestinal cancers, focusing on her area of clinical research, colorectal cancer. Dr Hubbard is the PI of several phase I clinical trials investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology, with a special interest in clinical and biologic markers of frailty. She is a member of the Cancer in the Elderly, as well as the Health Reported Outcomes and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network. She earned her MD from University of Minnesota Medical School.
  • Axel Grothey, MD

    Axel Grothey, MD

    Axel Grothey, MD

    Professor of Oncology

    Axel Grothey, MD, is a consultant in the Division of Medical Oncology, Department of Oncology, at Mayo Clinic in Rochester, Minnesota He is a professor of oncology and has teaching/examining privileges in Clinical & Translational Science at Mayo Graduate School, and is a member of Mayo Clinic’s Cancer Center. His clinical interests focus on gastrointestinal cancers, specifically, colorectal cancer, anti-angiogenesis, signal transduction inhibitors, and clinical trial design and statistics. Dr Grothey currently chairs the National Cancer Institute (NCI) Colon Cancer Task Force and is a member of the Gastrointestinal Cancer Steering Committee of the Alliance for Clinical Trials in Oncology. He received his medical degree at Ruhr-Universität Bochum in Germany.

Pediatric Neuroblastoma

  • Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Neuroblastoma Developmental Therapeutics Advanced Practice Nurse

    Jennifer Saggio received her graduate degree from the University of Pennsylvania’s School of Nursing. She has been a Nurse Practitioner at The Children’s Hospital of Philadelphia for the past 17 years. Over the past 9 years she has been part of the Neuroblastoma Developmental Therapeutics Team specializing in the care of children with relapsed and refractory Neuroblastoma.
  • Navin Pinto, MD

    Navin Pinto, MD

    Navin Pinto, MD

    Associate Professor of Pediatrics

    Navin R. Pinto, MD, is an attending physician at Seattle Children's Hospital and an associate professor of pediatrics at the University of Washington School of Medicine. Dr Pinto’s interests and expertise focus on the use of genetic sequencing technologies to develop more personalized treatment strategies (pharmacogenomics) for children, adolescents, and young adults with solid tumors. He is an active member in numerous professional societies, has authored or co-authored articles published in various peer-reviewed journals, and is involved in several Phase I trials at Seattle Children’s Hospital. He earned his medical degree from the St. Louis University School of Medicine, and completed his pediatrics residency and pediatric hematology-oncology fellowship at the University of Chicago.
  • Jason Shohet, MD

    Jason Shohet, MD

    Jason Shohet, MD

    Associate Professor of Pediatric Hematology and Oncology

    Jason Shohet, MD, PhD, is the research co-director, Neuroblastoma Program, at Texas Children’s Cancer Center and associate professor, Department of Pediatrics, Section of Hematology-Oncology at Baylor College of Medicine, both in Houston. Dr Shohet’s research focuses on developing better molecular targeted therapies for neuroblastoma and other solid tumors, with specific interest in cancer stem cell biology, cellular reprogramming/epigenetics, microRNA function as oncogenes and tumor suppressors, novel tumor markers, molecular targeted therapies for neuroblastoma and solid tumors, and transgenic and orthotopic models for neuroblastoma. He earned his MD and PhD from Boston University School of Medicine, and completed his internship, residency, and fellowship at Baylor College of Medicine.

Myeloproliferative Disorders

  • David Steensma, MD

    David Steensma, MD

    David Steensma, MD

    Associate Professor of Medicine

    David P. Steensma, MD, FACP, is an associate professor of medicine at Harvard Medical School, consulting physician at Brigham & Women’s Hospital, and a faculty member in the Division of Hematological Malignancies at Dana-Farber Cancer Institute in Boston, Massachusetts. He earned his MD from the University of Chicago’s Pritzker School of Medicine, and completed an internal medicine internship and residency and a combined hematology-oncology fellowship at the Mayo Graduate School of Medicine in Rochester, Minnesota. Dr Steensma’s primary clinical and research focus is myelodysplastic syndromes, and he maintains an active interest in marrow failure syndromes. He has more than 300 publications in peer-reviewed journals that include the New England Journal of Medicine, Blood, and Leukemia.
  • Gabriela Hobbs, MD

    Gabriela Hobbs, MD

    Gabriela Hobbs, MD

    Instructor in Medicine

    Gabriela S. Hobbs, MD, is an assistant in medicine at Massachusetts General Hospital (MGH) and an instructor of medicine at Harvard Medical School, both in Boston. She earned her medical degree from Mount Sinai School of Medicine in New York, completed an internal medicine residency at Brigham and Women’s Hospital in Boston, and completed a fellowship in hematology and oncology at Memorial Sloan Kettering Cancer Center in New York. Dr. Hobbs joined the faculty at MGH in 2014, where she established a myeloproliferative neoplasms (MPNs) clinic. Her goal as a clinician and investigator is to create a comprehensive MPN clinic and research program, with research focusing on conducting clinical trials for patients with MPNs.

Lung Immunotherapy

  • Roy Herbst, MD, PhD

    Roy Herbst, MD, PhD

    Roy Herbst, MD, PhD

    Ensign Professor of Medicine (Oncology), Professor of Pharmacology

    Roy S. Herbst, MD, PhD, is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut. Dr Herbst has led phase I development of several new-generation targeted agents for non-small cell lung cancer (NSCLC). His laboratory work, which focuses on immunotherapy angiogenesis, EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways, has been translated from preclinical to clinical settings in multiple Phase II and III studies. He has authored or co-authored more than 300 publications, including peer-reviewed journal articles, abstracts, and book chapters.
  • Naiyer A. Rizvi, MD

    Naiyer A. Rizvi, MD

    Naiyer A. Rizvi, MD

    Director of Thoracic Oncology and Director of Immunotherapeutics

    Naiyer A. Rizvi, MD, is a professor of medicine, the director of Thoracic Oncology and Phase I Immunotherapeutics for the Division of Hematology and Oncology, and the Price Chair in Clinical Translational Research at Columbia University Medical Center in New York. Prior to joining Columbia University Medical Center, his clinical research at Memorial Sloan Kettering Cancer played a significant role in the FDA approval path of a new class of immunotherapies, called immune checkpoint inhibitors, for melanoma and lung cancer. His research focus is studying mechanisms of sensitivity and resistance to immunotherapy. He oversees phase 1 immunotherapy research in solid tumors, and is conducting clinical studies of novel immunotherapy drugs and immunotherapy combinations.

Lung Cancer - EGFR

  • Geoffrey R. Oxnard, MD

    Geoffrey R. Oxnard, MD

    Geoffrey R. Oxnard, MD

    Assistant Professor of Medicine

    Geoffrey R. Oxnard, MD, is a thoracic oncologist at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School in Boston. Dr Oxnard’s research focuses on identifying subpopulations of lung cancer with unique clinical and molecular characteristics through collaborations with molecular pathologists and laboratory researchers, as well as performing research with colleagues in radiology and medical physics to explore better ways of analyzing response and progression in clinical trials and correlative research. He earned his medical degree from the University of Chicago Pritzker School of Medicine, completed his internal medicine residency at Massachusetts General Hospital, and his medical oncology fellowship at Memorial Sloan Kettering Cancer Center.

Lung Cancer - ALK

  • Geoffrey R. Oxnard, MD

    Geoffrey R. Oxnard, MD

    Geoffrey R. Oxnard, MD

    Assistant Professor of Medicine

    Geoffrey R. Oxnard, MD, is a thoracic oncologist at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School in Boston. Dr Oxnard’s research focuses on identifying subpopulations of lung cancer with unique clinical and molecular characteristics through collaborations with molecular pathologists and laboratory researchers, as well as performing research with colleagues in radiology and medical physics to explore better ways of analyzing response and progression in clinical trials and correlative research. He earned his medical degree from the University of Chicago Pritzker School of Medicine, completed his internal medicine residency at Massachusetts General Hospital, and his medical oncology fellowship at Memorial Sloan Kettering Cancer Center.

Gastric Cancer

  • Manish A. Shah, MD

    Manish A. Shah, MD

    Manish A. Shah, MD

    Director, Gastrointestinal Oncology Program

    Manish A. Shah, MD, is a distinguished peer-review funded investigator and has led several phase I, II, and III clinical and translational studies in patients with advanced gastrointestinal malignancies. He is director of the Gastrointestinal Oncology Program at Weill Cornell Medicine, co-director of the Center for Advanced Digestive Care, and director of the Gastrointestinal Oncology Research Laboratory. Dr Shah is chair of the scientific advisory board for the DeGregorio Family Foundation for Stomach and Esophageal Cancer Education and Research. He earned his MD from the Harvard Medical School/ MIT Health Sciences and Technology program, completed an internal medicine residency at Duke University Medical Center, and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center.
  • David H. Ilson, MD, PhD

    David H. Ilson, MD, PhD

    David H. Ilson, MD, PhD

    Professor of Medicine

    David H. Ilson, MD, PhD, is an attending physician and member at Memorial Sloan Kettering Cancer Center, and is professor of medicine at Weill-Cornell Medical College. His area of research interest is upper gastrointestinal cancer, with a focus on the study of new agents in advanced esophageal cancer, and the evaluation of novel agents in combined modality therapy programs in locally advanced disease. Dr Ilson sits on the GI committees of CALGB and RTOG, the Upper GI Cancer Guidelines Committee of NCCN, and currently chairs or co-chairs several national clinical trials in esophageal cancer. He earned his received his MD from New York University, and completed his internship and residency in internal medicine at Bellevue Hospital at New York University.

Breast Cancer: HER2 Positive

  • Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Medical Oncologist

    Harold J. Burstein, M.D., Ph.D. is an Associate Professor of Medicine at Harvard Medical School, and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women's Hospital. Dr. Burstein attended Harvard College, and earned his MD at Harvard Medical School where he also earned a PhD in immunology. He additionally has a master's degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital and in medical oncology at Dana-Farber.

    His clinical research interests include novel treatments for early- and advanced-stage breast cancer, and studies of quality of life and health behavior among women with breast cancer. Dr. Burstein has written widely on breast cancer in both traditional medical journals and on the web. Representative publications can be found in the New England Journal of Medicine, the Journal of Clinical Oncology, and other leading medical journals. He serves on international breast cancer committees including the NCCN Breast Cancer Panel, The St. Gallen Breast Cancer Panel, and the Alliance Breast Cancer Committee, and chairs the ASCO guidelines on endocrine therapy for breast cancer. Dr. Burstein an Associate Editor for Cancer Education at the Journal of Clinical Oncology.
  • Eric Winer, MD

    Eric Winer, MD

    Eric Winer, MD

    Director, Breast Oncology Center

    Eric P. Winer, MD, is professor of medicine at Harvard Medical School, chief, Division of Women's Cancers, the Thompson Chair in Breast Cancer Research, and chief clinical strategy officer at Dana-Farber Cancer Institute. He is the leader of the Dana-Farber/Harvard Cancer Center Breast Program, and is the principal investigator/director of the Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer. Dr Winer has designed and led phase I, II, and III clinical trials, and collaborates closely with psychosocial researchers, health services researchers, and basic and translational scientists. His group at Dana-Farber conducts a broad array of breast cancer research with the goal of extending the lives of individuals with breast cancer, and minimizing suffering and morbidity from the disease.

Breast Cancer: ASCO

  • Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Medical Oncologist

    Harold J. Burstein, M.D., Ph.D. is an Associate Professor of Medicine at Harvard Medical School, and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women's Hospital. Dr. Burstein attended Harvard College, and earned his MD at Harvard Medical School where he also earned a PhD in immunology. He additionally has a master's degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital and in medical oncology at Dana-Farber.

    His clinical research interests include novel treatments for early- and advanced-stage breast cancer, and studies of quality of life and health behavior among women with breast cancer. Dr. Burstein has written widely on breast cancer in both traditional medical journals and on the web. Representative publications can be found in the New England Journal of Medicine, the Journal of Clinical Oncology, and other leading medical journals. He serves on international breast cancer committees including the NCCN Breast Cancer Panel, The St. Gallen Breast Cancer Panel, and the Alliance Breast Cancer Committee, and chairs the ASCO guidelines on endocrine therapy for breast cancer. Dr. Burstein an Associate Editor for Cancer Education at the Journal of Clinical Oncology.

All Speakers

  • Wen Wee Ma, MBBS

    Wen Wee Ma, MBBS

    Wen Wee Ma, MBBS

    Senior Associate Consultant, Medical Oncology

    Wen Wee Ma, MBBS, is a senior associate consultant in the Division of Medical Oncology at Mayo Clinic, Rochester, Minnesota. He is a board-certified medical oncologist with expertise in gastrointestinal oncology and developmental therapeutics. His research focuses on early phase anti-cancer drug development, and the application in gastrointestinal malignancies, including colorectal and pancreatic cancers. Prior to joining Mayo Clinic in 2016, he was an associate professor of oncology and directed the gastrointestinal cancers drug development program at Roswell Park Cancer Institute in Buffalo, New York. He has authored and co-authored over 50 publications, including those in high impact journals such as New England Journal of Medicine and Journal of Clinical Oncology.
  • Joleen M. Hubbard, MD

    Joleen M. Hubbard, MD

    Joleen M. Hubbard, MD

    Assistant Professor of Oncology

    Joleen M. Hubbard, MD, is assistant professor of medical oncology at Mayo Clinic in Rochester, Minnesota, where is also the chair of the Gastrointestinal Tumor Group Practice. She specializes in the treatment of gastrointestinal cancers, focusing on her area of clinical research, colorectal cancer. Dr Hubbard is the PI of several phase I clinical trials investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology, with a special interest in clinical and biologic markers of frailty. She is a member of the Cancer in the Elderly, as well as the Health Reported Outcomes and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network. She earned her MD from University of Minnesota Medical School.
  • Axel Grothey, MD

    Axel Grothey, MD

    Axel Grothey, MD

    Professor of Oncology

    Axel Grothey, MD, is a consultant in the Division of Medical Oncology, Department of Oncology, at Mayo Clinic in Rochester, Minnesota He is a professor of oncology and has teaching/examining privileges in Clinical & Translational Science at Mayo Graduate School, and is a member of Mayo Clinic’s Cancer Center. His clinical interests focus on gastrointestinal cancers, specifically, colorectal cancer, anti-angiogenesis, signal transduction inhibitors, and clinical trial design and statistics. Dr Grothey currently chairs the National Cancer Institute (NCI) Colon Cancer Task Force and is a member of the Gastrointestinal Cancer Steering Committee of the Alliance for Clinical Trials in Oncology. He received his medical degree at Ruhr-Universität Bochum in Germany.
  • Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Neuroblastoma Developmental Therapeutics Advanced Practice Nurse

    Jennifer Saggio received her graduate degree from the University of Pennsylvania’s School of Nursing. She has been a Nurse Practitioner at The Children’s Hospital of Philadelphia for the past 17 years. Over the past 9 years she has been part of the Neuroblastoma Developmental Therapeutics Team specializing in the care of children with relapsed and refractory Neuroblastoma.
  • Navin Pinto, MD

    Navin Pinto, MD

    Navin Pinto, MD

    Associate Professor of Pediatrics

    Navin R. Pinto, MD, is an attending physician at Seattle Children's Hospital and an associate professor of pediatrics at the University of Washington School of Medicine. Dr Pinto’s interests and expertise focus on the use of genetic sequencing technologies to develop more personalized treatment strategies (pharmacogenomics) for children, adolescents, and young adults with solid tumors. He is an active member in numerous professional societies, has authored or co-authored articles published in various peer-reviewed journals, and is involved in several Phase I trials at Seattle Children’s Hospital. He earned his medical degree from the St. Louis University School of Medicine, and completed his pediatrics residency and pediatric hematology-oncology fellowship at the University of Chicago.
  • Jason Shohet, MD

    Jason Shohet, MD

    Jason Shohet, MD

    Associate Professor of Pediatric Hematology and Oncology

    Jason Shohet, MD, PhD, is the research co-director, Neuroblastoma Program, at Texas Children’s Cancer Center and associate professor, Department of Pediatrics, Section of Hematology-Oncology at Baylor College of Medicine, both in Houston. Dr Shohet’s research focuses on developing better molecular targeted therapies for neuroblastoma and other solid tumors, with specific interest in cancer stem cell biology, cellular reprogramming/epigenetics, microRNA function as oncogenes and tumor suppressors, novel tumor markers, molecular targeted therapies for neuroblastoma and solid tumors, and transgenic and orthotopic models for neuroblastoma. He earned his MD and PhD from Boston University School of Medicine, and completed his internship, residency, and fellowship at Baylor College of Medicine.
  • David Steensma, MD

    David Steensma, MD

    David Steensma, MD

    Associate Professor of Medicine

    David P. Steensma, MD, FACP, is an associate professor of medicine at Harvard Medical School, consulting physician at Brigham & Women’s Hospital, and a faculty member in the Division of Hematological Malignancies at Dana-Farber Cancer Institute in Boston, Massachusetts. He earned his MD from the University of Chicago’s Pritzker School of Medicine, and completed an internal medicine internship and residency and a combined hematology-oncology fellowship at the Mayo Graduate School of Medicine in Rochester, Minnesota. Dr Steensma’s primary clinical and research focus is myelodysplastic syndromes, and he maintains an active interest in marrow failure syndromes. He has more than 300 publications in peer-reviewed journals that include the New England Journal of Medicine, Blood, and Leukemia.
  • Gabriela Hobbs, MD

    Gabriela Hobbs, MD

    Gabriela Hobbs, MD

    Instructor in Medicine

    Gabriela S. Hobbs, MD, is an assistant in medicine at Massachusetts General Hospital (MGH) and an instructor of medicine at Harvard Medical School, both in Boston. She earned her medical degree from Mount Sinai School of Medicine in New York, completed an internal medicine residency at Brigham and Women’s Hospital in Boston, and completed a fellowship in hematology and oncology at Memorial Sloan Kettering Cancer Center in New York. Dr. Hobbs joined the faculty at MGH in 2014, where she established a myeloproliferative neoplasms (MPNs) clinic. Her goal as a clinician and investigator is to create a comprehensive MPN clinic and research program, with research focusing on conducting clinical trials for patients with MPNs.
  • Roy Herbst, MD, PhD

    Roy Herbst, MD, PhD

    Roy Herbst, MD, PhD

    Ensign Professor of Medicine (Oncology), Professor of Pharmacology

    Roy S. Herbst, MD, PhD, is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut. Dr Herbst has led phase I development of several new-generation targeted agents for non-small cell lung cancer (NSCLC). His laboratory work, which focuses on immunotherapy angiogenesis, EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways, has been translated from preclinical to clinical settings in multiple Phase II and III studies. He has authored or co-authored more than 300 publications, including peer-reviewed journal articles, abstracts, and book chapters.
  • Naiyer A. Rizvi, MD

    Naiyer A. Rizvi, MD

    Naiyer A. Rizvi, MD

    Director of Thoracic Oncology and Director of Immunotherapeutics

    Naiyer A. Rizvi, MD, is a professor of medicine, the director of Thoracic Oncology and Phase I Immunotherapeutics for the Division of Hematology and Oncology, and the Price Chair in Clinical Translational Research at Columbia University Medical Center in New York. Prior to joining Columbia University Medical Center, his clinical research at Memorial Sloan Kettering Cancer played a significant role in the FDA approval path of a new class of immunotherapies, called immune checkpoint inhibitors, for melanoma and lung cancer. His research focus is studying mechanisms of sensitivity and resistance to immunotherapy. He oversees phase 1 immunotherapy research in solid tumors, and is conducting clinical studies of novel immunotherapy drugs and immunotherapy combinations.
  • Geoffrey R. Oxnard, MD

    Geoffrey R. Oxnard, MD

    Geoffrey R. Oxnard, MD

    Assistant Professor of Medicine

    Geoffrey R. Oxnard, MD, is a thoracic oncologist at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School in Boston. Dr Oxnard’s research focuses on identifying subpopulations of lung cancer with unique clinical and molecular characteristics through collaborations with molecular pathologists and laboratory researchers, as well as performing research with colleagues in radiology and medical physics to explore better ways of analyzing response and progression in clinical trials and correlative research. He earned his medical degree from the University of Chicago Pritzker School of Medicine, completed his internal medicine residency at Massachusetts General Hospital, and his medical oncology fellowship at Memorial Sloan Kettering Cancer Center.
  • Manish A. Shah, MD

    Manish A. Shah, MD

    Manish A. Shah, MD

    Director, Gastrointestinal Oncology Program

    Manish A. Shah, MD, is a distinguished peer-review funded investigator and has led several phase I, II, and III clinical and translational studies in patients with advanced gastrointestinal malignancies. He is director of the Gastrointestinal Oncology Program at Weill Cornell Medicine, co-director of the Center for Advanced Digestive Care, and director of the Gastrointestinal Oncology Research Laboratory. Dr Shah is chair of the scientific advisory board for the DeGregorio Family Foundation for Stomach and Esophageal Cancer Education and Research. He earned his MD from the Harvard Medical School/ MIT Health Sciences and Technology program, completed an internal medicine residency at Duke University Medical Center, and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center.
  • David H. Ilson, MD, PhD

    David H. Ilson, MD, PhD

    David H. Ilson, MD, PhD

    Professor of Medicine

    David H. Ilson, MD, PhD, is an attending physician and member at Memorial Sloan Kettering Cancer Center, and is professor of medicine at Weill-Cornell Medical College. His area of research interest is upper gastrointestinal cancer, with a focus on the study of new agents in advanced esophageal cancer, and the evaluation of novel agents in combined modality therapy programs in locally advanced disease. Dr Ilson sits on the GI committees of CALGB and RTOG, the Upper GI Cancer Guidelines Committee of NCCN, and currently chairs or co-chairs several national clinical trials in esophageal cancer. He earned his received his MD from New York University, and completed his internship and residency in internal medicine at Bellevue Hospital at New York University.
  • Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Medical Oncologist

    Harold J. Burstein, M.D., Ph.D. is an Associate Professor of Medicine at Harvard Medical School, and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women's Hospital. Dr. Burstein attended Harvard College, and earned his MD at Harvard Medical School where he also earned a PhD in immunology. He additionally has a master's degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital and in medical oncology at Dana-Farber.

    His clinical research interests include novel treatments for early- and advanced-stage breast cancer, and studies of quality of life and health behavior among women with breast cancer. Dr. Burstein has written widely on breast cancer in both traditional medical journals and on the web. Representative publications can be found in the New England Journal of Medicine, the Journal of Clinical Oncology, and other leading medical journals. He serves on international breast cancer committees including the NCCN Breast Cancer Panel, The St. Gallen Breast Cancer Panel, and the Alliance Breast Cancer Committee, and chairs the ASCO guidelines on endocrine therapy for breast cancer. Dr. Burstein an Associate Editor for Cancer Education at the Journal of Clinical Oncology.
  • Eric Winer, MD

    Eric Winer, MD

    Eric Winer, MD

    Director, Breast Oncology Center

    Eric P. Winer, MD, is professor of medicine at Harvard Medical School, chief, Division of Women's Cancers, the Thompson Chair in Breast Cancer Research, and chief clinical strategy officer at Dana-Farber Cancer Institute. He is the leader of the Dana-Farber/Harvard Cancer Center Breast Program, and is the principal investigator/director of the Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer. Dr Winer has designed and led phase I, II, and III clinical trials, and collaborates closely with psychosocial researchers, health services researchers, and basic and translational scientists. His group at Dana-Farber conducts a broad array of breast cancer research with the goal of extending the lives of individuals with breast cancer, and minimizing suffering and morbidity from the disease.

Partners

Academic

  • logo-einstein

Associations

Publishers